PTO/SB/088 (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork R Substitute for form 1449/PTO

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/698,928 October 31, 2003 Filing Date Serge H. Boyer First Named Inventor 1626 Art Unit

SIAIL						Art Unit	1626		
	(Use as	many s	neels a	s necessary	<i>'</i>	Examiner Name	Taofiq A. Solola		
Sheet	1	1	of	1		Attorney Docket Number 2358.0180002/RWE/AES			
			_	N	ON PATENT	LITERATURE DOCUME	ENTS		
Examiner	Cite	1	nclude				f the article (when appropriate), title of	T	
Initials*	No. ¹				, magazine, jοι	ımal, serial, symposium, catal	og, etc.), date, page(s), volume issue	T ²	
	ļ					publisher, city and/or country			
\/m	SARTILLO-PISCIL, F., et al., "Fosfato-ésteres cíclicos diastereoisoméricos: 5-b								
7'4	NPL1	16	3011-2-	-tenoxi-2-	OXO-1,3,2-dio	xatostorinanos, precursore	s de radicales libres alquilo β- o no oxidativo," Rev. Soc. Quim.	l	
l l					of the Mexican Chemical S		I		
	 						clic diastereoisomeric phosphate	 	
	į	e	sters:	5-bromo	-4-phenyl-2-p	henoxy-2-oxo-1,3,2-dioxar	phosphorinanes, free β-		
	NPL2	: (r	phosp	hatoxy) a	alkyl radical p	recursors and cation radica	I generators in non-oxidative		
	į					lexico 46:330-334, Journal	of the Mexican Chemical Society		
	<u> </u>	(0	Decer	<u>mber 200</u>	(2)			<u> </u>	
Ì							tides Using Cesium Fluoride by the]	
	NPL3						10):1968-1973, The Chemical		
1		S	Society of Japan, Inc. (1985)						
			natiel	h translat	ion of TAKAK	II H et al "Synthesis of	Deavyribaaligaanucleatides Using		
1	NPL4		English translation of TAKAKU, H., et al., "Synthesis of Deoxyribooligonucleotides Using Cesium Fluoride by the Phosphotriester Approach," Nippon Kagaku Kaishi (no. 10):1968-						
			1973, The Chemical Society of Japan, Inc. (1985)						
	 	\dashv						 	
1	NPL5		THUONG, NT. and Chabrier, P., "Nouvelle méthode de préparation de la phosphorylcholine, de la phosphorylcholine et de leurs dérivés," <i>Bull. Soc. Chim.</i>						
	NPLS						eurs derives," Buil. Soc. Chim.		
				France 1-2:667-671, Masson and Co. (1974)					
j	į	E	nglisl	h translat	ion of THUON	NG, N.T. and Chabrier, P., '	'New Method for Preparation of	1	
- 1	NPL6	6 P	hosp	horyl cha	line, of phosp	horyl homocholine and the	ir derivatives," Bull. Soc. Chim.		
				1-2:667	-671, Masson	and Co. (1974)			
	NPL7	, c	ialog	File 351.	Accession N	o. 11683821, WPI English	language abstract of WO 97/49717		
			ī	2/3	1/27				
\dashv				010	197	***************************************		┝──	
1	NPL8	, c	ору с	of Office	Action for U.S	. Application No. 11/145,19	94, Mark D. Erion et al., filed June		
\// NPLO			3, 2005, mailed March 24, 2006						
	 								
								l .	
								Yes	
					 			<u> </u>	
	1								
		l l						1	

544158.1

Examiner Signature	T. A.	Solola	Date Considered	727-06
O.g.iditare	1 M	2010 W	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.18. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction Act of 1895 to persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwor

Substitute for form 1449/PTO JUN 1 3 2006 THIRD SUPPLEMENTAL INFORMATION D STATEMENT BY APPLY

Complete if Known Application Number 10/698,928 October 31, 2003 Filing Date First Named Inventor Serge H. Boyer Art Unit 1626 **Examiner Name** Taofiq A. Solola Attorney Docket Number 2358.0180002/RWE/AES

(Use as many sheets as necessary) Sheet of

			U.S. PATENT DO	CUMENTS		
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials No.		Number-Kind Code ^{2 (If Known)}] MM-DD-1111	Applicant of Cited Document	or Relevant Figures Appear	
40	US1	6,946,115	09/20/2005	Erion et al.		
	US2	3,328,388	06/27/1967	Shen et al.		
	US3	2002/0120130 A1	08/29/2002	Gosselin et al.		
<u> </u>	US4	2005/0101776 A1	05/12/2005	Gosselin et al.		
			•		1	

		Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code' Number' Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
10	FP1	NL6511420	03/03/1966	Merck & Co., Inc.		
	FP2	WO 95/07287 A1	03/16/1995	Centre National de la Recherche Scientifique		
	FP3	WO 97/49717 A1	12/31/1997	Fedorov, I.I. et al.		Abs
	<u> </u>					

544157_1.DOC

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for fo			7,79, 110 pc130	Complete if Known		
FOURTH	CLIDDI		PRITE A T	Application Number	10/698,928	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 31, 2003	
				First Named Inventor	Serge H. Boyer	
				Art Unit	1626	
(Use as many sheets as necessary)			is necessary)	Examiner Name	Taofiq A. Solola	
Sheet	1	of	1	Attorney Docket Number	2358.0180002/RWE/AES (MTI-046)	

Under the Paperwork Reduction Act of 1995, no per-

561024.1

			-
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²
10	C1	BOYER, S. et al., "The Discovery of MB07133: A HepDirect® Prodrug of Cytarabine Monophosphate for the Treatment of Hepatocellular Carcinoma," poster presentation at the American Chemical Society (ACS) Prospective, Boston, MA (May 2006).	
	C2	ERION, M. et al., "HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver", Current Opinion in Investigational Drugs 7(2): 109-117, The Thomson Corporation (2006).	
	С3	MA, B, et al., "A Phase I/II Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MB07133 in Subjects with Unresectable Hepatocellular Carcinoma (HCC) (Poster ID 2054, no. 19)," poster presentation at the American Society of Clinical Oncology (ASCO) Conference, Atlanta, Georgia (June 2006).	
•			

Examiner Date Signature 7-30-06 Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Rediction Act of 1995, no s are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known				
Application Number	10/698,928			
Filing Date	October 31, 2003			
First Named Inventor	Serge H. Boyer			
Art Unit	1626			
Examiner Name	Taofiq A. Solola			
Attorney Docket Number	2358.0180002/RWE/AES (MTI-046)			

			U.S. PATENT DO	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No.1	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
70	A1	5,854,231	12-29-1998	Camden	
	A2	6,037,335	03-14-2000	Takashima et al.	
					
			 		
		 			
					
			ļ <u></u>		

			FOREIGN PATE	ENT DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	
	<u></u>	Country Code' Number' Kind Code' (if known)	MM-DD- YYYY	Document	Figures Appear	Т6
70	B1	WO 95/07920	03-23-1995	Gilead Sciences	·	
			····			
			_			
	L					

561023.1

Examiner Signature	T.A.	Solo Car	Date Considered	7-30-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).' See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a perient by the public which is to like (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Page 150, Alexandria, VA 22313-1450.